insulin glargine
Brand: SOLIQUA 100/33
approved
Quick answer
insulin glargine (SOLIQUA 100/33), is a pharmaceutical active ingredient, with approved status in the US.
Key facts
- INN
- insulin glargine
- Brand
- SOLIQUA 100/33
- Route
- INJECTION
- Formulation
- INJECTABLE
Related news
FDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Enters Diabetes Market
FDA approves LANGLARA as interchangeable biosimilar to Lantus insulin glargine, marking Lannett Company's entry into diabetes treatment market through Lanexa Biologics.
Lilly's Foundayo Shows 57% Mortality Reduction in Landmark ACHIEVE-4 Diabetes Trial
Eli Lilly's Foundayo (orforglipron) demonstrates superior cardiovascular outcomes with 57% lower all-cause death risk vs insulin glargine in Phase 3 trial.
Frequently asked questions
What is insulin glargine?
insulin glargine (SOLIQUA 100/33), is a pharmaceutical active ingredient, with approved status in the US.
What is the brand name for insulin glargine?
SOLIQUA 100/33 is a marketed brand name for insulin glargine. Check FDA Drugs@FDA for the current US label holder.